JD Health International, Inc. (HK:6618)
:6618
Want to see HK:6618 full AI Analyst Report?
Top Page
JD Health International, Inc.
(6618)
Select Model
Select Model
Rating:71Outperform
Price Target:
HK$52.00
▼(-13.76% Downside)
Action:ReiteratedDate:03/24/26
The score is driven mainly by strong financial fundamentals (especially a very conservative balance sheet) and a constructive earnings-call outlook with robust growth and margin gains. This is tempered by weaker cash-flow consistency and clearly bearish technicals with the stock trading below major moving averages; valuation also looks demanding at ~30x earnings.
Positive Factors
Conservative balance sheet
Exceptionally low leverage and rising equity provide durable financial flexibility. This conservatism supports multi-year investments (AI, supply chain, pharmacies), reduces refinancing risk in stress, and gives optionality to fund growth or cushion cyclical healthcare headwinds without eroding core operations.
Negative Factors
Free cash flow reset
A meaningful decline in free cash flow reduces near-term financial flexibility and heightens reliance on operating performance or external funding for investments. If higher capex or working-capital needs persist, the company may face constrained ability to sustain discretionary spend or accelerate offline rollouts.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Exceptionally low leverage and rising equity provide durable financial flexibility. This conservatism supports multi-year investments (AI, supply chain, pharmacies), reduces refinancing risk in stress, and gives optionality to fund growth or cushion cyclical healthcare headwinds without eroding core operations.
Read all positive factors
JD Health International, Inc. (6618) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$144.87B
Dividend YieldN/A
Average Volume (3M)7.60M
Price to Earnings (P/E)30.1
Beta (1Y)1.44
Revenue Growth26.35%
EPS Growth28.38%
CountryHK
Employees3,564
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)1.07
Shares Outstanding3,210,775,100
10 Day Avg. Volume6,883,323
30 Day Avg. Volume7,596,953
Financial Highlights & Ratios
PEG Ratio1.20
Price to Book (P/B)2.62
Price to Sales (P/S)2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$74.59Price Target Upside23.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)1.85
Revenue Forecast (FY)HK$87.28B
JD Health International, Inc. Business Overview & Revenue Model
Company Description
JD Health International Inc., an investment holding company, operates an online healthcare platform in the People's Republic of China. It offers pharmaceutical and healthcare products, including OTC drugs, prescription drugs, and medical devices a...
JD Health International, Inc. Earnings Call Summary
Earnings Call Date:Mar 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 13, 2026
Earnings Call Sentiment Positive
The call presented a strongly positive operational and financial performance: double-digit revenue growth (26.3% YoY), materially higher non-IFRS profit growth (36.3% YoY), margin expansion, sizable user additions, heavy investment and traction in AI and product launches, and healthy operating cash flow. Challenges discussed were mostly execution and maturation-related (monetization of AI, rising S&M costs, offline economics, concentration of direct-sales revenue) rather than structural declines. On balance, the positive growth, margin improvements and strategic wins outweigh the cited risks and costs.Positive Updates
Strong Revenue Growth
Full-year 2025 revenue RMB 73.4 billion, up 26.3% year-over-year; Q4 2025 revenue RMB 21.0 billion, up 27.4% year-over-year; achieved >20% YoY revenue growth for four consecutive quarters.
Negative Updates
Rising Certain Operating Costs
Selling and marketing expenses rose ~26.9% year-over-year despite a largely flat S&M expense ratio (reported 5.2%); fulfillment expense ratio ticked up 0.2 percentage points to 10.4%, indicating cost pressures as the business scales.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Revenue Growth
Full-year 2025 revenue RMB 73.4 billion, up 26.3% year-over-year; Q4 2025 revenue RMB 21.0 billion, up 27.4% year-over-year; achieved >20% YoY revenue growth for four consecutive quarters.
Read all positive updates
Company Guidance
The management guided that JD Health will pursue continued high-quality growth by doubling down on its “super” pharmaceutical supply chain, direct‑sales engine and AI-enabled services while expanding online‑offline integration (no large‑scale M&A; offline/pharmacy expansion to be cautious and step‑by‑step). Key 2025 metrics they cited as the baseline for that guidance include FY revenue RMB73.4 billion (+26.3% YoY) and FY non‑IFRS profit RMB6.5 billion (+36.3%) with a margin of 8.9% (Q4 revenue RMB21.0 billion, +27.4%; Q4 non‑IFRS profit RMB1.1 billion, margin 5%); direct sales RMB60.9 billion (82.9% of revenue, +24.8%), service revenue RMB12.6 billion (17.1% of revenue, +34.1%), gross margin 24.8% (+1.9ppt), fulfillment expense ratio 10.4%, S&M ratio 5.2% (S&M spend +26.9%), R&D ratio 2.2% with 880+ R&D staff, operating cash flow RMB10.2 billion and cash/equivalents and related assets about RMB69.5 billion (net increase ~RMB10.1 billion). They expect AI and new drug launches to be major multi‑year drivers (>100 new drugs launched in 2025 vs ~30 in 2024; DAYVIGO >20,000 launch‑month orders; Dr. Da Wei: hundreds of millions of interactions, 98% satisfaction; JOY DOC: >5 million patients), will scale on‑demand retail and insurance payment (coverage in 29 cities), and will prioritize sustainable margin and user growth (220 million annual active user accounts, +34 million net adds).JD Health International, Inc. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 71.54B | 58.16B | 53.53B | 46.74B | 30.68B |
| Gross Profit | 17.73B | 13.31B | 11.87B | 9.89B | 7.20B |
| EBITDA | 3.97B | 1.31B | 2.93B | -60.93M | -1.37B |
| Net Income | 5.24B | 4.16B | 2.14B | 380.11M | -1.07B |
Balance Sheet | |||||
| Total Assets | 81.62B | 71.27B | 64.29B | 61.28B | 48.00B |
| Cash, Cash Equivalents and Short-Term Investments | 47.00B | 51.24B | 41.22B | 47.67B | 41.99B |
| Total Debt | 636.29M | 258.39M | 214.75M | 199.41M | 201.27M |
| Total Liabilities | 21.52B | 16.03B | 14.92B | 16.49B | 8.15B |
| Stockholders Equity | 60.10B | 55.23B | 49.36B | 44.78B | 39.85B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | 4.29B | 4.54B | 5.86B | 2.93B |
| Operating Cash Flow | 9.94B | 4.33B | 4.60B | 5.91B | 3.43B |
| Investing Cash Flow | -575.36M | 3.15B | -8.02B | -4.24B | -17.75B |
| Financing Cash Flow | -77.10M | -45.61M | -117.20M | -925.45M | -163.65M |
JD Health International, Inc. Technical Analysis
Negative
60.30
Price Trends
53.09
Negative
57.47
Negative
57.89
Negative
Market Momentum
-1.03
Negative
45.45
Neutral
47.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6618, the sentiment is Negative. The current price of 60.3 is above the 20-day moving average (MA) of 48.98, above the 50-day MA of 53.09, and above the 200-day MA of 57.89, indicating a bearish trend. The MACD of -1.03 indicates Negative momentum. The RSI at 45.45 is Neutral, neither overbought nor oversold. The STOCH value of 47.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6618.
JD Health International, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$144.87B | 30.12 | 9.03% | ― | 26.35% | 28.38% | |
71 Outperform | HK$682.16M | 2.28 | 5.29% | 9.14% | -1.48% | 549.60% | |
68 Neutral | HK$7.11B | 7.50 | 15.36% | 2.61% | 7.60% | 17.41% | |
67 Neutral | HK$1.40B | 5.35 | 18.05% | 4.37% | -4.23% | 3.95% | |
62 Neutral | HK$7.27B | 43.03 | 0.62% | ― | -9.81% | -72.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$6.41B | -6.17 | -10.66% | 2.38% | -5.73% | -442.94% |
* Healthcare Sector Average
HK:6618
JD Health International, Inc.
44.74
7.99
21.74%
HK:1526
Rici Healthcare Holdings Ltd.
0.88
-0.11
-11.11%
HK:1951
Jinxin Fertility Group Ltd.
2.41
-0.49
-16.90%
HK:2273
Gushengtang Holdings Limited
30.10
-1.03
-3.31%
HK:3689
Guangdong Kanghua Healthcare Co., Ltd. Class H
2.02
0.23
12.85%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
11.67
-2.29
-16.40%
JD Health International, Inc. Corporate Events
JD Health Delivers Record 2025 Profit on AI-Driven Healthcare Expansion
Mar 5, 2026
JD Health reported strong audited results for 2025, with revenue rising 26.3% to RMB73.4 billion and gross profit climbing 36.7%, supported by its AI-enabled, full-scenario healthcare services ecosystem and omnichannel supply chain. Non-IFRS profi...
JD Health Sets March 5, 2026 Board Meeting to Approve 2025 Results and Mull Dividend
Feb 20, 2026
JD Health International Inc. has scheduled a board meeting for March 5, 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended December 31, 2025, and to consider whether to recommend a final ...
JD Health Grants 536,489 Share Awards to Employees Under Post-IPO Scheme
Jan 1, 2026
JD Health International Inc. has granted 536,489 share awards, equivalent to about 0.02% of its issued share capital as of the grant date, to employees of the group (excluding directors and senior management) under its post-IPO share award scheme,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.